Navigation Links
Reportlinker Adds Global Anti-CD20 Monoclonal Antibodies Industry
Date:10/4/2010

0

Rising Number of MAbs Under Clinical Trials II-30

High Costs Impede MAbs Penetration II-30

Opportunities in Technology Development II-31

Advancements & Challenges in Antibody Production Processes II-31

Increasing Demand for Protein A in MAb Manufacturing II-32

6. RECENT DRUG APPROVALS AND REGULATORY STATUS II-33

RITUXAN RECEIVES FDA APPROVAL FOR THE TREATMENT OF Chronic

Lymphocytic Leukemia II-33

GSK Receives Positive Opinion for Arzerra™ from EMEA II-33

LFB Obtains Orphan Drug Status for LFB-R603 in Europe II-34

FDA Grants Accelerated Approval for GSK and Genmab's

Ofatumumab for Chronic Lymphocytic Leukemia II-34

InNexus's DXL625 Receives Positive Opinion from FDA II-34

Spectrum Pharma Obtains FDA Approval for Zevalin's Expanded

Label in NHL Treatment II-35

Bayer Schering Obtains EU Approval for Zevalin in First-Line

Treatment II-35

7. RECENT INDUSTRY ACTIVITY II-36

Pfizer Discontinues Development of TRU-015; Continues to

Develop SBI-087 II-36

Roche and Biogen Discontinue Ocrelizumab Development in

Rheumatoid Arthritis II-36

Roche and Biogen File Patent Suit Against GSK II-37

Ocrelizumab Meets Primary End-Point In Phase III Trial for RA II-37

Rituxan Plus FC Chemotherapy Shows Improved Survival in

Treatment-Naïve CLL Patients II-37

FDA Declines Early Use of Rituxan in RA II-38

LG Life Sciences Announces New Anti-CD20 Antibody Program II-38

Provenance Acquires Global Rights to New Anti-CD20 Antibody

from Merck II-38

Roche Takes Over Genentech II-39

Pfizer Acquires Wyeth II-39

Spectrum Pharma Acquires Lymphoma Drug Zevalin II-39

Biogen Partners with Genentech and Roche for Development of

GA-101 II-39

Roche, GlycArt and Genentech Team Up for Development of GA-101 II-40

InNexus Biotechnology Discov
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Reportlinker Adds US Disposable Medical Supplies Market Report
2. Reportlinker Adds Gilead Sciences Inc.: PharmaVitae Profile
3. Reportlinker Adds Drug Delivery Partnering Agreements in Pharma and Biotech
4. Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery
5. Reportlinker Adds Reinventing Pharmaceutical Sales Forces
6. Reportlinker Adds Computer Assisted Coding Of Medical Information Market Shares, Strategies, and Forecasts 2008 to 2014
7. Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery
8. Reportlinker Adds Global Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015
9. Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities
10. Reportlinker Adds Global Top 10 Chemical Companies -- Industry, Financial and SWOT Analysis
11. Reportlinker Adds Pharma 101: An Overview of the Life Sciences Industry (Analyst Insight)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Celsion Corporation (the "Company") ... it has received commitments from institutional investors to ... the Company,s common stock in an at-the-market registered ... fund. The Company entered into definitive ... the Company agreed to sell an aggregate of ...
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ... Trading (OFT) approval condition to the announced tender offer for ...   As a result of the waiver, the ... expects to complete the tender offer on January 24, 2014 ... of all of the remaining conditions to the tender offer. ...
(Date:1/15/2014)... 15, 2014 BreedIT Corp (OTC: ... worldwide distributor of highly sophisticated agro-breeding solutions for plant ... 2014, the Company,s board of directors appointed chemistry and ... its new member of the board. From ... Teva Pharmaceutical Industries Ltd (NYSE: TEVA ) ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... , RIDGEFIELD, Conn., Aug. 25 Results of ... Warfarin, Compared to Dabigatran)(1) study will be presented at the ... Aug. 30. The primary objective of RE-LY was to ... thrombin inhibitor, dabigatran etexilate, against the current standard therapy, warfarin, ...
... August 25 20% of parents seek medical,help because ... baby,and the accompanying discomfort (crying). Reputed medical journal "Archives,of ... recently,published the results of the clinical research project that ... department of the Brussels,University Hospital. , ...
Cached Medicine Technology:Data From Largest Stroke Prevention Trial in Atrial Fibrillation To Premiere at European Society of Cardiology Congress 2Data From Largest Stroke Prevention Trial in Atrial Fibrillation To Premiere at European Society of Cardiology Congress 3Data From Largest Stroke Prevention Trial in Atrial Fibrillation To Premiere at European Society of Cardiology Congress 4Data From Largest Stroke Prevention Trial in Atrial Fibrillation To Premiere at European Society of Cardiology Congress 5Data From Largest Stroke Prevention Trial in Atrial Fibrillation To Premiere at European Society of Cardiology Congress 6Data From Largest Stroke Prevention Trial in Atrial Fibrillation To Premiere at European Society of Cardiology Congress 7Medical World Recognises New Therapy for Reflux Babies 2
(Date:4/14/2014)... centers around the world, many people live and work ... that block sunlight. And as the global population continues ... darkness will only spread. , To alleviate the ... that redirects sunlight onto narrow streets and alleyways. The ... edge at an angle, where it spreads sunlight onto ...
(Date:4/14/2014)... associate professor of chemical engineering at Virginia Tech ... efficiently analyze living cells. The long-term goal is to ... , In his lab , Lu and his ... molecular events inside cells. These devices promote high sensitivity ... of cells. , Based on their record of achievements, ...
(Date:4/14/2014)... April 2014, Perth, Australia. Drug discovery company Proteomics ... development of a companion diagnostic (CDx) test with ... , The research team authenticated the panel of ... control samples. Seven biomarkers were validated at high ... , The mass spectrometry data was then cross-validated ...
(Date:4/14/2014)... guidelines for high-risk bladder cancer, chemotherapy before or ... clinical practice. The findings are published early online ... the American Cancer Society. , Clinical trials have ... muscle-invasive bladder cancer who are given chemotherapy before ... after surgery also improves survival. To investigate the ...
(Date:4/11/2014)... insights into the processes that control brain cell production ... and other brain-related disorders. , Scientists have gained new ... that controls how and when nerve and brain cells ... to develop and keeps it healthy. Their findings could ... of control, which is a fundamental characteristic of many ...
Breaking Medicine News(10 mins):Health News:Let the sun shine in: Redirecting sunlight to urban alleyways 2Health News:Efficient analysis of small quantity of cells improves chances to understand disease 2
... HealthDay Reporter , THURSDAY, Sept. 16 (HealthDay News) -- ... cancer, new research finds. Prior research has shown higher ... this study is among the first to show that lower ... as gastrointestinal bleeding -- may also be effective, said Eric ...
... of fertilizer that feeds breast cancer progression, significantly ... researchers at UCLA,s Jonsson Comprehensive Cancer Center have ... the immune cells that are trying to fight ... the body against disease into aiders and abettors. ...
... By Amanda Gardner HealthDay Reporter , WEDNESDAY, ... Wednesday over whether the diet drug Meridia should be pulled ... risk of heart attack and stroke. Members of an ... said the drug should remain available to consumers called for ...
... Reporter , WEDNESDAY, Sept. 15 (HealthDay News) -- Children with ... that is, yawn in response to seeing others yawn, a ... contagion," an unconscious response that reflects a recognition of how ... and others is an important step in a child,s social ...
... WEDNESDAY, Sept. 15 (HealthDay News) -- When people with chronic ... the level of hemoglobin cells in their blood should go ... levels don,t increase by much, these "poor responders" experience a ... Reporting in the Sept. 16 issue of the New ...
... Center at the University of California, San Diego has ... the American College of Radiology (ACR). ... and this prestigious certificate recognizes our extraordinary effort," said ... Moores UCSD Cancer Center. "ACR leads the way toward ...
Cached Medicine News:Health News:Low-Dose Aspirin May Reduce Colon Cancer Risk 2Health News:Low-Dose Aspirin May Reduce Colon Cancer Risk 3Health News:Stress accelerates breast cancer progression in mice 2Health News:Stress accelerates breast cancer progression in mice 3Health News:Stress accelerates breast cancer progression in mice 4Health News:FDA Advisers Divided on Whether to Ban Diet Drug Meridia 2Health News:FDA Advisers Divided on Whether to Ban Diet Drug Meridia 3Health News:Autistic Children Don't Seem to Yawn 'Contagiously' 2Health News:Autistic Children Don't Seem to Yawn 'Contagiously' 3Health News:Anemia Drugs Could Pose Threat to Some Kidney Patients 2Health News:Anemia Drugs Could Pose Threat to Some Kidney Patients 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: